PURPOSE: The aim of this study was to evaluate the efficacy of @entity7855 and success of treatment in particular etiological causes in @entity323 lasting more than 3 months. MATERIAL AND METHODS: A total of 141 @entity1 between 27 and 78 years old without any cardiac compromise, despite controversial, which precludes @entity7855 (Viagra) treatment, were included in this study. All @entity1 had only International Index of Erectile Capacity Form (IIEF) for pre-treatment evaluation and 50 mg @entity7855 was started. @entity1 were assessed monthly for 6 months thereafter. Erectile capacity changes were questioned by IIEF on each follow-up and 100 mg @entity7855 was given in @entity1 without a response and monthly follow-up was scheduled. All @entity1 had SMA-12, hormonal analyses and penile colour Doppler ultrasonography during the treatment course. The difference between IIEF score of each @entity1 was displayed by Paired-t test and p-values less than 0.05 was applied as significant. RESULTS: The average beginning IIEF score of 141 @entity1 was 11.80 +/- 0.47 [6-22], and increased to 20.70 +/- 0.62 [6-30] after a month of 50 mg @entity7855 treatment. The mean increase was 75.4% and found to be significant (p = 0.000, p < 0.05). The average IIEF scores were recorded as 22.57 +/- 0.69 after 3, and 22.12 +/- 0.24 after 6 months. There was no difference between these values and 2nd month controls (P3 month = 0.5675, P6 month = 0.6138, p > 0.05). A positive response was recorded in 102 @entity1 (72.3%) and 39 (27.7%) @entity1 were unresponsive. Doubled doses of @entity7855 (100 mg) was effective in additional 17 @entity1 . After overall treatment, 119 (84.4%) @entity1 had benefit from @entity7855 . Penile Doppler ultrasonography displayed @entity9085 in 79 (56.03%), @entity5501 in 14 (9.93%), mixt vascular pathology in 14 (9.93%) @entity1 . Normal ultrasonographic findings in 32 @entity1 (22.7%) were classified as @entity409 . Among the organic causes, @entity7855 was found to be most effective in @entity9085 group. CONCLUSION: @entity7855 is a successful management modality in @entity323 with minimal pre-treatment evaluation. As far as etiological causes concerned, @entity7855 was found to be most effective in @entity9085 group and psychogenic group. The efficacy of @entity7855 treatment has not been changed with the treatment time, since IIEF scores were stable during follow-up controls.

The efficacy of @entity7855 in different etiologies of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction'] @entity409 :: ('MESH:D008107', 'Disease') :: ['psychogenic dysfunction'] @entity9085 :: ('MESH:D014715', 'Disease') :: ['arterial insufficiency'] @entity7855 :: ('MESH:C101426', 'Chemical') :: ['sildenafil', 'Sildenafil'] @entity5501 :: ('MESH:D006504', 'Disease') :: ['veno-occlusive dysfunction']
@entity323 :: (MESH:D007172,Disease) :: ['erectile dysfunction']
